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Aims: Obesity defined by body mass index (BMI) is characterized by better prognosis and lower plasma N-terminal pro- 
B-type natriuretic peptide (NT-proBNP) in heart failure. We assessed whether another anthropometric measure, per 
cent body fat (PBF), reveals different associations with outcome and heart failure biomarkers (NT-proBNP, high-sensi- 
tivity troponin T (hs-TnT), soluble suppression of tumorigenesis-2 (sST2)). 
Methods: In an individual patient dataset, BMI was calculated as weight (kg)/height (m)2, and PBF through the Jackson– 
Pollock and Gallagher equations. 
Results: Out of 6468 patients (median 68 years, 78% men, 76% ischaemic heart failure, 90% reduced ejection fraction), 
24% died over 2.2 years (1.5–2.9), 17% from cardiovascular death. Median PBF was 26.9% (22.4–33.0%) with the Jackson– 
Pollock equation, and 28.0% (23.8–33.5%) with the Gallagher equation, with an extremely strong correlation (r  0.996, p 
< 0.001). Patients in the first PBF tertile had the worst prognosis, while patients in the second and third tertile had 
similar survival. The risks of all-cause and cardiovascular death decreased by up to 36% and 27%, respectively, per each 
doubling of PBF. Furthermore, prognosis was better in the second or third PBF tertiles than in the first tertile regardless 
of model variables. Both BMI and PBF were inverse predictors of NT-proBNP,  but not hs-TnT.  In obese patients    (BMI 
c 30 kg/m2, third PBF tertile), hs-TnT and sST2, but not NT-proBNP, independently predicted outcome. 
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Conclusion: In parallel with increasing BMI or PBF there is an improvement in patient prognosis and a decrease in NT-









Obesity is a growing public health problem and signifi- 
cantly increases the risk of several disorders, including 
coronary artery disease and heart failure.1 However, 
once a patient develops heart failure, overweight and 
mild-to-moderate obesity are associated with better sur- 
vival compared with patients with normal weight.2,3 
Several explanations have been proposed for this 
‘obesity paradox’, which has also been described in other 
chronic disorders.4,5 For example, obese patients tend to 
be younger, and have greater energy reserves and less 
muscle depletion.6,7 They also display an atte- nuated 
response to sympathetic and renin–angiotensin– system 
activation, and tolerate better drugs for neurohormonal 
antagonism because they are often hypertensive at 
treatment initiation.6,7 Higher insulin concentrations 
may also exert positive effects on the autonomic nervous 
system and the pituitary–adrenal axis, manifesting as 
reduced peripheral vascular resistances.8 
Despite these facts, existence of an obesity paradox 
has been questioned by considering that all evidence 
derives from studies using body mass index (BMI), a 
simple measure that is not informative on the amount and 
distribution of body fat.9 Most notably, a recent study on 
1738 heart failure patients showed that a higher waist-to-
hip ratio (WHR), an indicator of abdominal obesity, 
predicts a higher risk of death among women.10 The 
authors thus challenged the obes- ity paradox, 
postulating that ‘fat deposition is patho- physiologically 
harmful and may be a target for therapy in female 
patients with [heart failure]’.10 
In the field of heart failure biomarkers, another  
paradox described is that of the decrease in circulating 
natriuretic peptides among overweight and obese 
patients.11,12 Mechanisms underlying this inverse asso- 
ciation between BMI and natriuretic peptides have not 
been clarified so far, although some possible explan- 
ations have been proposed, largely focused on reduced 
production of B-type natriuretic peptide (BNP) or the 
N-terminal fraction of pro-BNP (NT-proBNP), rather 
than their clearance.11,13 Importantly, the influence of 
BMI or body composition on high-sensitivity troponin 
T (hs-TnT) or soluble suppression of tumorigenesis-2 
(sST2), two biomarkers useful for risk stratification in 
heart failure,14,15 has not been established so far. 
To clarify these points, in a large individual heart  
failure patient dataset designed to assess the prognostic 
value of heart failure biomarkers we evaluated: a) the 
relationship between BMI and per cent body fat (PBF), 
as a measure of body composition, and patient prog- 
nosis; b) the relationship between BMI and PBF with 




Search strategy, study selection 
In April 2017, studies evaluating hs-TnT and prognosis 
in chronic heart failure were searched in four databases 
(Medline, EMBASE, Cochrane Library and Scopus) to 
perform an individual patient data meta-analysis on hs- 
TnT and prognosis.14 For the present analysis, patients 
with BMI data available were considered (6468 out of 
9289, 70%). All patients had data on all-cause death, 
while information on cardiovascular death was avail- 
able for 6262 (97%). 
 
Anthropometric measures 
BMI was calculated as weight (kg)/height2 (m2). Patients 
were stratified into the following categories, according 
to the World Health Organization: under- weight (BMI 
< 18.5 kg/m2), normal weight (18.5– 
24.9 kg/m2), overweight (25–29.9 kg/m2), obesity class I 
(30–34.9 kg/m2), obesity class II (35–39.9 kg/m2), obes- 
ity class III ( 40 kg/m2).16 PBF was estimated from BMI, 
gender and age through  the  Jackson–Pollock  and 




In all studies NT-proBNP was measured through the 
ECLIA monoclonal method (Roche Diagnostics®), sST2 
with the Presage® assay, and TnT through a hs- assay 












characteristics of these assays are presented in dedi- 
cated papers.20–22 These biomarkers were dosed in a core 
laboratory for each study; NT-proBNP and hs- TnT were 
dosed during each of the six original studies or shortly 
after their completion, while sST2 was mea- sured on the 
stored samples. The estimated glomerular filtration rate 
(eGFR) was calculated through the Chronic Kidney 
Disease Epidemiology collaboration equation.23 
 
Statistical analysis 
IBM SPSS Statistics (version 22, 2013) and R statistical 
software (http://www.r-project.org/, version 3.4.4)24 
were used. Normal distribution was assessed through the 
Kolmogorov–Smirnov test; variables with normal 
distribution were presented as mean standard devi- ation, 
while those with non-normal distribution as median and 
interquartile interval. NT-proBNP,  hs-  TnT and sST2 
were log2-transformed. Mean differences among groups 
were evaluated through the unpaired Student t test. 
Categorical variables  were  compared  by the Chi-square 
test with  Yates  correction. Pearson’s product moment 
correlation coefficient (r) was calculated as a measure of 
linear association between variables. The log-rank  test  
(Mantel–Cox) was used to compare survival times on 
Kaplan–Meier curves. Cubic spline interpolation was 
carried out to represent the changes in risk according to 
biomarker values; five knots were considered. The BMI 
value for which hazard ratio 1 was chosen as the value 
corres- ponding to the inflection point of the curve, above 
which the slope of the curve becomes steeper. Except for 
NT-proBNP, hs-TnT and sST2, all univariate pre- 
dictors of all-cause death with a p value < 0.10 were 
included in the multivariate analysis: age, gender, 
ischaemic aetiology, estimated glomerular filtration  rate 
(eGFR), left ventricular ejection fraction (LVEF), New 
York Heart Association (NYHA) class I–II vs. III–IV, 
hypertension, chronic obstructive pulmonary disease 
(COPD), diabetes, atrial fibrillation, high- sensitivity C-
reactive protein (hs-CRP), therapy with angiotensin-
converting enzyme inhibitors/angiotensin- receptor 
blockers (ACEis/ARBs), beta-blockers, min- 
eralocorticoid receptor antagonists (MRAs). 
Multicollinearity was searched by calculating the 
Variance Inflation Factor. The Schoenfeld Residuals 
Test was used to test the proportional hazard assump- 
tion in Cox model; time-dependent variables were used 
when this assumption was not met. The ‘one-in-10’ rule 
was followed to avoid model overfitting. In Cox regres- 
sion analysis, the Fine–Gray model was used to  account 
for mutually exclusive endpoints; non-cardio- vascular 
death was considered as competing risk for 
cardiovascular death. The net reclassification 
improvement (with risk categories set at <10%, 10– 30% 
and >30%) and the integrated discrimination 
improvement were calculated to assess reclassification. 
Two-tailed p values <0.05 were considered significant. 
 
Results 
Population characteristics across categories of 
body mass index 
The   main   characteristics   of   patients    evaluated  (N 
6468) are summarized in  Table  1.  Median  age was 68 
years (interquartile interval 58–76), and the majority of 
patients (n 5071,  78%)  were  men,  and had heart failure 
with ischaemic aetiology (n 3650, 76%). The overall 
median LVEF was 27% (21–34%), and the vast majority 
of patients (n 5848, 90%) had heart failure with reduced 
ejection fraction. Renal func- tion was moderately 
impaired, with a median eGFR of 57 mL/min per 1.73 
m2 (44–68). Median circulating NT-proBNP, hs-TnT 
and sST2 were 1359 ng/L (513– 3229), 18 ng/L (9–33) 
and 27 ng/mL (20–39), 
respectively. 
Patients in the different BMI categories were hetero- 
geneous in many respects. Most notably, age decreased 
with increasing BMI, the prevalence of hypertension and 
diabetes became progressively higher, glomerular 
filtration rate and LVEF increased, and NT-proBNP 
decreased (Table 1). 
 
BMI and prognosis 
Over a median 2.2-year follow-up (1.5–2.9), 1546 
patients (24%) died, and cardiovascular death occurred 
in 1088 patients, out of 6262 with available data (17%). 
The shortest survival free from these endpoints was 
recorded for patients with BMI <18.5 kg/m2; survival 
increased progressively from underweight to normal 
weight and overweight patients, and was not signifi- 
cantly different from overweight to grade III obesity 
(Supplemental Figure 1). When stratifying the popula- 
tion according to the 25 and 30 BMI cut-offs, patients 
with BMI <25 had a worse prognosis than those with 
BMI 25–30 or 30, whose survival was similar 
(Supplemental Figure 2). The same conclusion was 
reached for both male (all-cause death: log-rank 53.1,   p 
< 0.001;   cardiovascular   death:    log-rank    29.1,   p < 
0.001) and female patients (all-cause death: log- rank 
14.2, p 0.001;  cardiovascular  death:  log-rank  7.2, p 
0.027). Additionally, the spline curves in the whole 
population as well as in men and  women  showed a 
progressive improvement in prognosis up to 25 kg/m2 
BMI (Supplemental Figures 3 and 4). 
In the prognostic model including age, gender, 













Table 1. Population characteristics. 
 
 All  BMI categories  
 
N ¼ 6468 
 
<18.5 
n ¼ 90 (1%) 
18.5–24.9 
n ¼ 2221 (34%) 
25.0–29.9 
n ¼ 2780 (43%) 
30.0–34.9 
n ¼ 1051 (16%) 
35.0–39.9 
n ¼ 235 (4%) 
c40 
n ¼ 91 (1%) 
 
p 
Age, years 68 (58–76) 74 (67–82) 72 (64–79) 67 (59–75) 63 (54–72) 59 (49–64) 54 (42–62) <0.001 
Men, n (%) 5071 (78) 38 (42) 1676 (76) 2294 (83) 840 (80) 175 (75) 48 (53) <0.001 
BMI, kg/m2 26.6 (23.8–29.9) 17.4 (16.6–18.0) 23.0 (21.5–24.0) 27.1 (26.0–28.4) 31.8 (30.7–33.3) 36.7 (35.7–37.9) 42.6 (40.6–45.3) <0.001 
Ischaemic aetiology, n (%) 3650 (76) 45 (50) 1276 (58) 1639 (59) 548 (52) 105 (45) 37 (41) <0.001 
NYHA I–II/III–IV, n (%) 3715/2381 (57/37) 36/45 (40/50) 1194/889 (54/40) 1700/946 (61/34) 618/369 (59/35) 129/89 (55/38) 38/43 (42/47) <0.001 
Hypertension, n (%) 2905 (45) 35 (39) 854 (39) 1285 (46) 545 (52) 137 (58) 49 (54) <0.001 
Diabetes, n (%) 1721 (27) 10 (11) 477 (22) 727 (26) 359 (34) 104 (44) 44 (48) <0.001 
AF, n (%) 1056 (16) 11 (12) 353 (16) 456 (16) 179 (17) 42 (18) 15 (17) 0.767 
COPD, n (%) 864 (13) 24 (27) 292 (13) 350 (13) 156 (15) 30 (13) 12 (13) 0.001 
LVEF, % 27 (21–34) 26 (21–32) 26 (20–34) 27 (21–34) 27 (22–33) 27 (20–32) 30 (23–35) <0.001 
LVEF <40%, 40–49%, 5848, 411, 172 78, 6, 5 2015, 146, 46 2538, 166, 63 930, 73,41 209, 16, 10 78, 4, 7 0.002 
c50%, n (%) (90, 6, 3) (87, 7, 6) (91, 7, 2) (91, 6, 2) (89, 7, 4) (89, 7, 4) (86, 4, 8) 
eGFR, mL/min per 1.73 m2 57 (44–68) 48 (34–70) 55 (42–65) 56 (44–67) 58 (47–67) 59 (50–70) 63 (47–71) <0.001 
hs-CRP, mg/L 4.6 (1.8–9.8) 2.5 (1.1–8.3) 4.4 (1.5–9.8) 4.2 (1.8–9.5) 5.5 (2.5–11.3) 6.3 (2.6–9.6) 7.9 (5.4–11.5) <0.001 
NT-proBNP, ng/L 1359 (513–3229) 3861 (1254–8368) 2336 (956–4956) 1356 (550–2761) 854 (319–1961) 546 (246–1200) 357 (144–938) <0.001 
hs-TnT, ng/L 18 (9–33) 18 (13–34) 20 (11–41) 17 (10–31) 17 (9–29) 14 (9–25) 13 (5–20) 0.001 
sST2, ng/mL 27 (20–39) 31 (22–36) 29 (21–43) 27 (20–38) 26 (20–36) 25 (20–33) 27 (19–33) 0.004 
ACEi/ARB, n (%) 5722 (89) 73 (81) 1955 (88) 2461 (89) 946 (90) 207 (88) 80 (88) 0.171 
BB, n (%) 3128 (48) 37 (41) 1018 (46) 1376 (50) 539 (51) 122 (52) 36 (40) 0.005 
MRA, n (%) 1113 (17) 23 (26) 394 (18) 464 (17) 186 (18) 34 (15) 12 (13) 0.167 
Significant p values are reported in bold. 
ACEi/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AF: atrial fibrillation; BB: beta-blocker; BMI: body mass index; COPD: chronic obstructive pulmonary disease; eGFR: 
estimated glomerular filtration rate; hs-CRP: high-sensitivity C-reactive protein; hs-TnT: high-sensitivity troponin T; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonists; NT- 
proBNP: N-terminal fraction of pro-B-type natriuretic peptide; NYHA: New York Heart Association; sST2: soluble suppression of tumorigenesis-2. 
 
All-cause death CV death 
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2130 1922 1251 507 316 141 2077 1876 1212 476 293 126 
2117 1866 1211 462 269 114 2057 1813 1168 426 244 99 
 
Figure 1. Per cent body fat and patient survival. 
Per cent body fat is estimated based on the Jackson–Pollock formula. Patients (Pts) are stratified according to tertiles of per cent body 
fat. When using the Gallagher formula, the log-rank values for all-cause death and cardiovascular (CV) death were 13.3 (p ¼ 0.001), 





















Figure 2. Per cent body fat and prognosis: spline curve analysis. 
Spline curve analysis. Per cent body fat is calculated using the Jackson–Pollock equation. The inflection points of the curves are: 27.9% 
(all-cause death) and 27.6% (cardiovascular (CV) death). When using the Gallagher equation, the inflection points of the curves for all- 
cause death are 26.2 and 26.6%, respectively. 
HR: hazard ratio 
 
III–IV, hypertension, COPD, diabetes, atrial fibrilla- 
tion, hs-CRP, ACEi/ARB, beta blockers and MRA 
therapy, patients with BMI 25 kg/m2 cut-off had  a better 
prognosis for  all-cause  death  (hazard  ratio 0.74,   95%    
confidence    interval    (CI)    0.66–0.84; p < 0.001) and 
cardiovascular  death  (hazard  ratio 0.80, 95% CI 0.70–
0.91; p ¼ 0.001). 
PBF: estimates and prognostic value 
Median PBF was 26.9% (22.4–33.0%) with the 
Jackson–Pollock equation, and 28.0% (23.8–33.5%) 
with the Gallagher equation, with an extremely strong 
correlation (r 0.996, p < 0.001). Patient characteristics 
across PBF tertiles are provided in Supplemental 
% body fat 




















Table 2. Percent body fat (PBF) as predictor of outcome. 
All-cause death Cardiovascular death 
  
Doubling of PBF  1st  vs. 2ndþ3rd tertiles Doubling of PBF  1st vs. 2ndþ3rd tertiles 
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p 
Jackson-Pollock    0.68    0.58–0.80    <0.001    0.79     0.70–0.89     <0.001     0.76    0.64–0.91    0.003    0.85      0.74–0.98 0.025 
Gallagher 0.64    0.53–0.77    <0.001    0.79     0.70–0.90     <0.001     0.73    0.60–0.90    0.003    0.86      0.74–0.98  0.025 
The risk is calculating per each doubling of PBF (by considering log2-transformed variables) or the first vs. the second and third tertiles (Jackson-Pollock 
equation: <23.9% vs. c23.9%; Gallagher equation: <25.1% vs. c25.1%). 
The model for multivariate analysis includes age, gender, ischaemic aetiology, estimated glomerular filtration rate (eGFR), left ventricular ejection 
fraction (LVEF), New York Heart Association (NYHA) class I-II vs. III-IV, hypertension, chronic obstructive pulmonary disease (COPD), diabetes, atrial 
fibrillation, hs-C-reactive protein (hs-CRP), therapy with angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEi/ARB), beta- 
blockers (BB), mineralocorticoid receptor antagonists (MRA). 
CI: confidence interval; HR: hazard ratio. 
 
 
Table 2. Patients in the first PBF tertile had the worst 
prognosis, while patients in the second and third tertiles 
had similar survival (Figure 1). The improvement in 
patient prognosis with increasing PBF, in the whole 
population and in both genders, was visually repre- 
sented by spline curves (Figure 2 and Supplemental 
Figure 5). 
In the prognostic model above, PBF independently 
predicted all-cause and cardiovascular mortality. In 
detail, the risks of all-cause and cardiovascular death 
decreased by up to 36% and 27%, respectively,  per each 
doubling of PBF (Table 2). Furthermore, progno- sis was 
better in the second or third tertiles than in the first tertile 
regardless of model variables (Table 2). In both cases 
(i.e. considering absolute PBF values or first tertile vs. 
second or third tertile) metrics of risk reclas- sification 
were improved (Supplemental Table 3). 
 
Plasma NT-proBNP, hs-TnT and sST2 according 
to BMI and PBF 
As stated above, the decrease in NT-proBNP with 
increasing BMI category was much more prominent than 
variations observed in either hs-TnT or sST2, des- pite 
significant differences for all three biomarkers (Figure 
3). Accordingly, though weak, the correlation between   
BMI   and    NT-proBNP    was    stronger    (r    0.257)  
than  the  correlation  with  either  hs-TnT (r 0.057) or 
sST2 (r 0.107; all p < 0.001). In multi- variate linear 
regression analysis, when considering the same model 
used for prognostic assessment, BMI inde- pendently 
predicted both NT-proBNP and sST2,  but not hs-TnT 
(Supplemental Table 4). Similar results were found for 
PBF (Supplemental Tables 2 and 4). 
The three biomarkers were then added to the prog- 
nostic  model  above.   In   the   obese   subgroup   (BMI 
30 kg/m2) and in the third PBF tertile, NT- proBNP was 
not an independent predictor of outcome, 
in contrast to both hs-TnT and sST2. This pattern was 
not observed across the other BMI or PBF categories 
(Table 3 and Supplemental Table 5). 
 
Discussion 
This analysis, performed in a large individual heart fail- 
ure patient dataset designed to assess the prognostic 
value of biomarkers, confirms that overweight and 
obese heart failure patients have longer survival, and 
provides the first demonstration of a direct relationship 
between body fat content and better outcome. We also 
report that obesity influences NT-proBNP considerably 
more than hs-TnT and sST2, and NT-proBNP 
appeared less prognostic in a model including hs-TnT 
or sST2 among obese patients. 
The better prognosis of obese heart failure patients 
is so counterintuitive that it has been attributed to 
limitations of BMI as a synthetic anthropometric 
measure.9 To verify this hypothesis, sophisticated 
evaluations of body composition such as bioelectrical 
impedance analysis should be performed. 
Unfortunately, large datasets of heart failure patients 
with these measures are not available, and even a very 
simple index such as the WHR has been assessed only 
in a single cohort of limited size (n 1479), including 
patients with either acute or chronic heart failure.10 
One may also consider the WHR to be a measure 
reflecting both subcutaneous and visceral abdominal 
fat, also influenced by hip size (so that WHR should 
preferably be measured together with waist circumfer- 
ence).25 In the search for measures more closely cor- 
related to body composition than BMI, more accurate 
than WHR, and potentially available from large popu- 
lation datasets, we estimated the percentage of body 
weight composed of fat tissue. We used two equations 
introduced and validated against direct measurements 





Figure 3. Circulating biomarkers across categories of body mass index (BMI) and per cent body fat (PBF) tertiles. 
All p values are <0.001. PBF is calculated through the Jackson–Pollock equation (first tertile: <23.9%; second tertile: 23.9-30.5%; third 
tertile: c30.5%). 




Table 3. Biomarkers and prognosis across body mass index (BMI) categories. 




BMI c30 kg/m2 
HR 95% CI p HR 95% CI p 
 
NT-proBNP 1.01 0.84–1.22 0.883 1.04 0.85–1.26 0.729 
hs-TnT 1.47 1.19–1.82 <0.001 1.45 1.15–1.82 0.002 
sST2 
BMI 25-29.9 kg/m2 
1.71 1.19–1.82 <0.001 1.83 1.25–2.69 0.002 
NT-proBNP 1.21 1.07–1.37 0.002 1.17 1.02–1.34 0.024 
hs-TnT 1.19 1.04–1.35 0.011 1.19 1.02–1.38 0.024 
sST2 1.02 0.80–1.30 0.873 1.10 0.84–1.44 0.485 
BMI 18.5-24.9 kg/m2       
NT-proBNP 1.17 1.03–1.32 0.014 1.11 0.97–1.28 0.120 
hs-TnT 1.22 1.09–1.36 <0.001 1.29 1.14–1.46 <0.001 
sST2 1.28 1.08–1.53 0.006 1.28 1.05–1.57 0.017 
hs-TnT: high-sensitivity troponin T; NT-proBNP: N-terminal fraction of pro-B-type natriuretic peptide; sST2: soluble 
suppression of tumorigenesis-2. 
 
PBF displayed a very strong correlation (r 0.996). A 
higher PBF was consistently associated with lower all- 
cause and cardiovascular mortality.  Accordingly, spline 
curves showed a progressive improvement in 
prognosis up to a PBF around 27%, beyond which 
patient prognosis remained  basically  stable.  Both  PBF 
(modelled continuously) and the first versus second or 
third PBF tertiles were independent 
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predictors of outcome and improved metrics of risk 
reclassification in a model including several baseline 
variables with prognostic significance (age, gender, 
ischaemic aetiology, eGFR, LVEF, NYHA class, sev- 
eral comorbidities, hs-CRP and medical therapy). 
To the best of our knowledge, we are the first to assess 
PBF in patients with heart  failure,  and  to report that 
patients with higher PBF have lower all- cause and 
cardiovascular mortality, as well as lower  NT-proBNP, 
but not hs-TnT or sST2, levels. While assessing this 
point was the main goal of our analysis, these results 
deserve considerations also from the per- spective of 
prognostic stratification. Most notably, we observed that 
patients with BMI 25 kg/m2 had a 26% lower risk of all-
cause mortality, and a 20% lower risk of cardiovascular 
mortality, regardless of other baseline variables. 
Similarly, patient prognosis was better in the second or 
third PBF tertiles than in the first tertile. A simple and 
widely used measure such as the BMI, and possibly also 
PBF estimates through simple equations, should then be 
considered for the prediction of fatal endpoints in heart 
failure outpatients. 
With regard to NT-proBNP, hs-TnT and sST2,  which 
rank among the strongest predictors of outcome in heart 
failure,14,15 the influence of BMI or PBF was much more 
prominent for NT-proBNP than for sST2 and hs-TnT, as 
demonstrated through correlation and multivariate linear 
regression analyses. Interestingly, the three biomarkers 
were independent predictor of outcome in all BMI 
categories and  PBF  tertiles,  except for obese patients 
(BMI 30 kg/m2) or the high- est PBF tertile, where only 
hs-TnT and sST2 remained independent predictors of 
all-cause and cardiovascular mortality, arguably 
establishing these biomarkers as the tests of choice for 
refined prognostication in obese patients with heart 
failure. 
 
Study limitations and perspectives for future studies 
Some limitations of this hypothesis-generating study 
must be acknowledged. First, although our results 
provide a quite compelling demonstration of the link 
between higher PBF and longer survival in heart fail- 
ure, it is important to notice that PBF was estimated 
through equations developed and validated in healthy 
subjects. These results should then be verified in pro- 
spective studies using direct measurements of body 
composition or anthropometric measures, as in prior 
studies.28–30 Second, the number of underweight indi- 
viduals was low, possibly because underweight heart 
failure patients often have cardiac cachexia or advanced, 
life-limiting disorders, and such patients were not 
enrolled in clinical trials; because  of  the  poor prognosis 
of these underweight patients, their inclusion    in    the    
analysis    would    have    further 
strengthened the proposed relationship  between  BMI or 
PBF and outcome. Third, our dataset did not allow  to 
assess the nutritional status of these patients, which 
might hold prognostic significance,31 and did not include 
many variables related to metabolic disturb- ances and 
cardiovascular risk (such as lipid profile, liver steatosis, 
alcohol intake or exercise) or echocar- diographic 
parameters (for example, indices of dia- stolic function 
or hypertrophy patterns). Fourth, no information was 
available regarding the changes in weight, BMI or PBF 
over time, although the temporal trends of these 
parameters might hold prognostic sig- nificance. Future 
studies exploring these aspects are warranted. 
 
Conclusions 
In parallel with increasing BMI or PBF there is an 
improvement in patient prognosis and a decrease in NT-
proBNP, but not hs-TnT  or  sST2.  hs-TnT  or sST2 are 
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